DRUG INDUCED ACUTE INTERSTITIAL NEPHRITIS AND VASCULITIS IN RENAL ALLOGRAFT: CASE REPORT

Volume: 39 Number: 1 March 1, 2000
  • Sait Şen
  • Reyhan Yeğen
  • Ercan Ok
  • Gülçin Başdemir
Ege Journal of Medicine Cover
Ege Journal of Medicine
PDF Download
EN TR

DRUG INDUCED ACUTE INTERSTITIAL NEPHRITIS AND VASCULITIS IN RENAL ALLOGRAFT: CASE REPORT

Abstract

Intimal arteritis, severe interstitial infiltration and severe tubulitis have been found in the renal allograft biopsy (RAB) of a patient who had acute renal allograft dysfunction after two weeks of renal transplantation. Since vasculitis is accepted as a finding of acute rejection, we have diagnosed the biopsy as acute vascular rejection (grade llb, Banff 93). But drug induced acute interstitial nephritis (AIN) Which was one of the clinical prediagnosis couldn't be excluded. Before the RAB, his trimethaprim-sulfamethoxazole (TMP-SMZ) treatment was discontinued. Renal functions began to improve and finally reached baseline Without antirejection therapy after biopsy. Clinicopathological findings sugge st that renal pathology has developed as a drug reaction (TMP-SMZ) and the patient has been evaluated as AIN and vasculitis due to drug use. This is the first vasculitis due to drug use of renal transplant patient. After five years of follow-up renal allograft functions are normal and the patient is well.

Keywords

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Sait Şen

Reyhan Yeğen

Ercan Ok

Gülçin Başdemir

Publication Date

March 1, 2000

Submission Date

March 1, 2000

Acceptance Date

-

Published in Issue

Year 2000 Volume: 39 Number: 1

IZ

https://izlik.org/JA27NU43XT

Cite

RIS / Bibtex
Vancouver
1.Sait Şen, Reyhan Yeğen, Ercan Ok, Gülçin Başdemir. BÖBREK TRANSPLANTLI OLGUDA İLACA BAGL! AKUT İNTERSTİSYEL NEFRİT VE VASKÜLİT: OLGU SUNUMU. EJM [Internet]. 2000 Mar. 1;39(1):69-72. Available from: https://izlik.org/JA27NU43XT

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.